Theriva Biologics
TOVX
20 hedge funds and large institutions have $177K invested in Theriva Biologics in 2025 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 4 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
40% more capital invested
Capital invested by funds: $126K → $177K (+$50.8K)
18% more funds holding
Funds holding: 17 → 20 (+3)
1.34% more ownership
Funds ownership: 3.21% → 4.55% (+1.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$26.8K |
| 2 |
Jane Street
New York
|
+$15.9K |
| 3 |
Two Sigma Advisers
New York
|
+$11.8K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$9.91K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.09K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$15.6K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$7.73K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.3K |
| 4 |
BlackRock
New York
|
-$27 |
| 5 |
PW
Pandora Wealth
Oakbrook Terrace,
Illinois
|
-$2 |
TOVX Hedge Fund Activity: Q3 2025 in Review
20 of the 7,635 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q3 2025, worth a combined $177K — up 40% from $126K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new TOVX positions and 4 closed out — a net gain of 3 holders — while 5 added to existing stakes and 2 trimmed.
The largest buyer was Two Sigma Investments, opening a new position worth an estimated $26.8K. The largest seller was Citadel Advisors, exiting entirely with an estimated $15.6K sold.
- 20 institutional investors held Theriva Biologics (TOVX) as of Q3 2025, up from 17 in Q2 2025.
- Funds reported $177K of Theriva Biologics stock for Q3 2025, up 40% quarter-over-quarter.
- 7 funds opened new Theriva Biologics positions in Q3 2025 and 4 closed out, a net change of +3 holders.
- The largest Theriva Biologics buyer in Q3 2025 was Two Sigma Investments, an estimated $26.8K added.
- The largest Theriva Biologics seller in Q3 2025 was Citadel Advisors, an estimated $15.6K sold.
Based on aggregated 13F filings for Q3 2025.